Leo Wealth LLC Acquires New Shares in Gilead Sciences, Inc. $GILD

Leo Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,973 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

Several other large investors also recently made changes to their positions in the business. Bank of Nova Scotia purchased a new stake in Gilead Sciences during the 2nd quarter worth $100,056,000. OMERS ADMINISTRATION Corp purchased a new position in Gilead Sciences in the second quarter valued at about $55,754,000. Groupe la Francaise raised its position in Gilead Sciences by 30.9% in the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the period. Baird Financial Group Inc. raised its position in Gilead Sciences by 3.6% in the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after purchasing an additional 10,206 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Gilead Sciences during the second quarter worth about $6,251,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the insider directly owned 113,684 shares in the company, valued at $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst commentary suggests Gilead could be substantially undervalued if new oncology trial data validate the company’s pipeline and create a larger long-term growth opportunity. Gilead Stock Could Be 50% Undervalued on New Oncology Trial News
• Positive Sentiment: Gilead reached an agreement with Canada’s pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), improving potential access and commercial prospects for the primary biliary cholangitis treatment. Gilead Reaches Canadian Reimbursement Agreement for LYVDELZI
• Positive Sentiment: An analyst raised the company’s fiscal 2026 EPS forecast, providing a modest fundamental tailwind ahead of earnings. FY2026 EPS Forecast for Gilead Sciences Raised
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide therapies, potentially strengthening the company’s longer-term growth strategy and business-development profile. Gilead Deal Shows Big Pharma Appetite for Oral Peptides
• Neutral Sentiment: Gilead is preparing to report third-quarter results. Strong HIV sales, Yeztugo momentum and oncology developments could support the shares, but analysts also flag competitive pressure. Gilead Q3 Earnings Preview
• Neutral Sentiment: Wall Street’s pre-earnings estimates focus on revenue, earnings and operating metrics for the quarter ended September 2026; the reports offer expectations but do not represent released results. Gilead Q3 Wall Street Estimates
• Negative Sentiment: Exchange-traded funds were reported as net sellers of Gilead shares on October 23, indicating some short-term institutional selling pressure. ETFs Are Net Sellers of Gilead

Gilead Sciences Price Performance

Shares of GILD stock opened at $159.08 on Wednesday. The firm has a fifty day moving average of $149.65 and a two-hundred day moving average of $139.13. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $160.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the prior year, the firm earned $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GILD shares. Royal Bank Of Canada upped their target price on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. HSBC boosted their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Morgan Stanley decreased their price target on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $159.81.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.